Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.59 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894155 | 0.90 | L3MBTL1 (0.64) | GAATSHRATMRAB9A | |
| SCHEMBL893028 | 0.90 | TSHR (0.61) | HCRTR1HCRTR2PKMTSHRATM | |
| SCHEMBL13570495 | 0.90 | PKM (0.72) | USP2GAAHCRTR1HCRTR2PKM | |
| SCHEMBL894013 | 0.90 | ATM (0.67) | TSHRATMLMNA | |
| SCHEMBL893874 | 0.90 | TRPA1 (0.58) | USP2GAAHCRTR1HCRTR2PKM | |
| SCHEMBL894018 | 0.89 | TSHR (0.59) | HCRTR1HCRTR2PKMTSHRATM | |
| SCHEMBL894313 | 0.89 | ALDH1A1 (0.62) | PKMTSHRATM | |
| SCHEMBL893043 | 0.89 | TSHR (0.57) | USP2GAAHCRTR1HCRTR2PKM | |
| SCHEMBL893740 | 0.89 | TSHR (0.61) | HCRTR1HCRTR2TSHRATMLMNA | |
| SCHEMBL893894 | 0.89 | TSHR (0.61) | PKMTSHRATMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | claimed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | USP2 3472/4885GAA 3240/4885HCRTR1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.